EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Applied first-line systemic treatments, treatment modifications and outcomes in non-oncogenic metastatic non-small cell lung cancer in the Netherlands in 2019–2020: A nationwide study

J W Ankersmid-Matos Miguel, N L van Veen, W Jacobs, R A M Damhuis, C F van Uden-Kraan, E M W van de Garde, Santeon VBHC Lung Cancer Research Group

Cancer Epidemiology · 2025

DOI: 10.1016/j.canep.2025.102809 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Epidemiology, 2025. Verfasst von J W Ankersmid-Matos Miguel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Santeon, Utrecht, the Netherlands. Electronic address: j.ankersmid@santeon.nl. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The treatment landscape for patients with metastatic non-small cell lung cancer (mNSCLC) is rapidly evolving as new therapies are continually introduced. This study aimed to provide a contemporary overview of how patients diagnosed with mNSCLC in the Netherlands are treated in routine clinical practice, how applied systemic treatments are tolerated and with which overall survival (OS). METHODS: This nationwide retrospective study utilised data from the Netherlands Cancer Registry (NCR) complemented by electronic health records data of patients diagnosed with stage IV non-oncogenic mNSCLC in the years 2019-2020. First-line (1 L) treatments and corresponding overall survival (OS) were identified and compared across hospital types (academic, teaching, general), along with a multivariable analysis of 1 L treatment, patient, and tumour characteristics. In a subset of seven teaching hospitals, dose adjustments, early discontinuations and follow-up treatments were also assessed together with ESMO guideline adherence based on ECOG scores and levels of PD-L1 tumour expression. RESULTS: The total sample comprised 9511 patients (56 % male and mean age 68 years) of which 4485 (47 %) received best supportive care (BSC) only. The most frequently applied 1 L systemic treatment was chemo-immunotherapy with 51 % one-year survival. Starting any 1 L systemic treatment was more frequent among patients with younger age, better performance status, PD-L1 > 50 %, and those with their diagnosis established in an academic hospital. Chemotherapy was discontinued early ( = 2 and PD-L1 1-49 % group (30 %). CONCLUSIONS: Best supportive care over systemic treatment and chemotherapy treatment modifications are common in patients with mNSCLC. Presenting information to patients about these outcomes can support shared-decision making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleNetherlandsAgedRetrospective StudiesMiddle AgedRegistriesAged, 80 and over

Stichwörter der Autor:innen

Applied treatmentsLung cancerMNSCLCNetherlandsReal-world data

Autor:innen und Institutionen

  • Santeon, Utrecht, the Netherlands. Electronic address: j.ankersmid@santeon.nl.
  • Santeon, Utrecht, the Netherlands.
  • Department of Pulmonology, Martini Hospital, Groningen, the Netherlands.
  • Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands.
  • Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein, Utrecht, the Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University…

Förderung

  • Dutch Cancer Society

Zitieren

APA

Miguel, J. W. A., van Veen, N. L., Jacobs, W., Damhuis, R. A. M., van Uden-Kraan, C. F., van de Garde, E. M. W., & Santeon VBHC Lung Cancer Research Group (2025). Applied first-line systemic treatments, treatment modifications and outcomes in non-oncogenic metastatic non-small cell lung cancer in the Netherlands in 2019–2020: A nationwide study. Cancer Epidemiology. https://doi.org/10.1016/j.canep.2025.102809

Vancouver

Miguel JWA, van Veen NL, Jacobs W, Damhuis RAM, van Uden-Kraan CF, van de Garde EMW, et al. Applied first-line systemic treatments, treatment modifications and outcomes in non-oncogenic metastatic non-small cell lung cancer in the Netherlands in 2019–2020: A nationwide study. Cancer Epidemiology. 2025. doi:10.1016/j.canep.2025.102809

BibTeX
@article{Miguel2025,
  author = {Miguel, J W Ankersmid-Matos and van Veen, N L and Jacobs, W and Damhuis, R A M and van Uden-Kraan, C F and van de Garde, E M W and Santeon VBHC Lung Cancer Research Group, Santeon VBHC Lung Cancer Research Group},
  title = {Applied first-line systemic treatments, treatment modifications and outcomes in non-oncogenic metastatic non-small cell lung cancer in the Netherlands in 2019–2020: A nationwide study},
  journal = {Cancer Epidemiology},
  year = {2025},
  doi = {10.1016/j.canep.2025.102809}
}
Kostenlos starten →